J 2022

Myopia Control in European Children - Study Protocol and Methodology

KOMÍNEK, Martin, Rudolf AUTRATA, Inka KREJČÍŘOVÁ, Barbora ŽAJDLÍKOVÁ, J. HEISSIGEROVÁ et. al.

Basic information

Original name

Myopia Control in European Children - Study Protocol and Methodology

Authors

KOMÍNEK, Martin (203 Czech Republic, guarantor, belonging to the institution), Rudolf AUTRATA (203 Czech Republic, belonging to the institution), Inka KREJČÍŘOVÁ (203 Czech Republic, belonging to the institution), Barbora ŽAJDLÍKOVÁ (203 Czech Republic, belonging to the institution), J. HEISSIGEROVÁ (203 Czech Republic), M. KORBASOVÁ (203 Czech Republic), P. STUDENÝ (203 Czech Republic), M. DOSTÁLEK (203 Czech Republic), M. HLOŽÁNEK (203 Czech Republic) and Jana UNAR VINKLEROVÁ (203 Czech Republic, belonging to the institution)

Edition

HSOA Journal of Neonatology and Clinical Pediatrics, Herndon, VA 20171, USA, Herald Scholarly Open Access, 2022, 2378-878X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14110/22:00127211

Organization unit

Faculty of Medicine

Keywords (in Czech)

Atropine eye drops; Axial length of eye; Low dose atropine; Myopia in children; Progressive myopia

Keywords in English

Atropine eye drops; Axial length of eye; Low dose atropine; Myopia in children; Progressive myopia

Tags

International impact, Reviewed
Změněno: 26/1/2023 13:13, Mgr. Tereza Miškechová

Abstract

V originále

Purpose To report study protocol and methodology of multicentre, Randomized, double-blind, placebo-controlled study of the efficacy and safety of low dose atropine eye drops (0.02%, 0.04%) in slowing the progression of short-sightedness (myopia) in children. M.A.R.S. (Myopia and Atropin ReStriction). Conclusion M.A.R.S. clinical trial will enrich the knowledge about myopia and its possible treatment in the early stages in European children. It will be beneficial for paediatric patients, practicing paediatricians and ophthalmologist. In the future it will be helpful not only from a medical point of view, but also in economic aspect of management of progression of myopia in children and all the entire population.

Links

NU21-07-00189, research and development project
Name: Randomizovaná dvojitě zaslepená placebem kontrolovaná multicentrická studie účinnosti a bezpečnosti vysoce ředěného atropinového collyria při zpomalování rozvoje krátkozrakosti u dětí.
Investor: Ministry of Health of the CR, Subprogram 1 - standard
90128, large research infrastructures
Name: CZECRIN III